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ABSTRACT
Colorectal cancer (CRC) is one of the most common malignant neoplasms 
worldwide. Except for the existing fecal occult blood test, colonoscopy and 
sigmoidoscopy, no widely accepted in vitro diagnostic methods have been available. 
To identify potential peptide biomarkers for CRC, serum samples from a discovery 
cohort (100 CRC patients and 100 healthy controls) and an independent validation 
cohort (91 CRC patients and 91 healthy controls) were collected. Peptides were 
fractionated by weak cation exchange magnetic beads (MB-WCX) and analysed by 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF MS). Five peptides (peaks at m/z 1895.3, 2020.9, 2080.7, 2656.8 and 3238.5) 
were identified as candidate biomarkers for CRC. A diagnostic panel based on the five 
peptides can discriminate CRC patients from healthy controls, with an accuracy of 
91.8%, sensitivity of 95.6%, and specificity of 87.9% in the validation cohort. Peptide 
peaks at m/z 1895.3, 2020.9 and 3238.5 were identified as the partial sequences of 
complement component 4 (C4), complement component 3 (C3) and fibrinogen α chain 
(FGA), respectively. This study potentiated peptidomic analysis as  a promising in vitro 
diagnostic tool for diagnosis of CRC. The identified peptides suggest the involvement 
of the C3, C4 and FGA in CRC pathogenesis.
INTRODUCTION
Colorectal cancer (CRC) is the 3rd most common 
cancer among men (after lung and prostate cancer) and the 
2nd most frequent cancer among women after breast cancer 
[1]. In 2012, 1.4 million new cases of CRC and nearly 0.7 
million CRC-related deaths occurred worldwide [2]. The 
5-years relative survival rate for localized CRC is 90.3%, 
and it decreases to 70.4% and 12.5% when the cancer 
has spread to the adjacent organs and distant organs, 
respectively [3]. Early diagnosis of CRC is an effective 
way to prolong the lives of CRC patients [3].
The American Cancer Society (ACS) recommends 
that individuals who are over 50 years old should schedule 
one of the following screenings: (1) a high-sensitivity fecal 
occult blood test (FOBT) every year, (2) a stool DNA test 
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every 3 years, (3) a flexible sigmoidoscopy (FSIG) every 
5 years, (4) a double-contrast barium enema every 5 years, 
(5) a computed tomography (CT) colonography every 5 
years, or (6) a colonoscopy every 10 years [4]. However, 
due to the discomfort or high cost of these screening 
methods, only 55% of subjects aged 50 to 64 years have 
undergone a CRC screening test as suggested [5]. An 
examination of the entire colon by colonoscopy remains 
the golden standard for CRC screening, but people are 
hesitant to schedule a colonoscopy examination due to the 
complicated bowel preparation, associated discomfort, 
potential complications and high cost [6-9]. Although 
flexible sigmoidoscopy is less invasive than colonoscopy, 
this method is unable to examine the entire colon [10]. 
FOBT is non-invasive and economical, but it has relatively 
low sensitivity [11]. Carcinoembryonic antigen (CEA) 
has been extensively used as a blood-based marker for 
CRC prognosis [12], but it cannot be used as a diagnostic 
marker due to its relatively low specificity [13]. Currently, 
new blood-based tests that are accurate, safe, inexpensive, 
widely available, and associated with minimum patient 
discomfort are urgently required for the diagnosis of CRC.
The low-molecular-weight (LMW; ≤10kDa) serum 
peptidome represents the array of endogenous peptides that 
present in both intracellular and extracellular space of the 
body [14]. It contains several physiologically important 
peptides, such as peptide hormones, peptide metabolic 
products and proteolytic fragments of larger precursor 
proteins [15]. The proteolytic degradative patterns in the 
serum peptidome, often refer to as peptidome signature 
or fingerprint, hold important information about many 
physiological and pathological processes, such as aging 
[16], type 2 diabetes [17] and Alzheimer’s disease [18]. 
The progress of tumor’s malignancy is accompanied 
by alterations in exoproteases activities, affecting the 
constitution of endogenous peptides that can indicate the 
presence/absence of cancer [19]. The profiling of the serum 
peptidome has been used for the diagnosis of CRC in several 
studies [20–30]. Fan et al (2006) recruited 72 CRC patients 
and 65 healthy controls and randomly divided them into two 
groups: a model construction group and a validation group 
[20]. They established a diagnostic model with two peptides 
that yielded a sensitivity of 94.74% and a specificity of 
100% in the model construction phase and a sensitivity of 
94.12% and a specificity of 100% in the validation phase 
[20]. Several peptidome diagnostic models for CRC were 
also created by Deng et al (2013) [21], Liu et al (2006) [24] 
and Pietrowska et al (2012) [25]. However, these studies 
were hampered with small sample sizes, lacked independent 
validation or peptide identification.
The cancer-related biomarkers occur in blood at 
very low concentration levels. Immunoglobulins, albumin 
and other 20 proteins that make up approximately 99% of 
the protein content of serum can mask other proteins or 
peptides [15]. Therefore, it is imperative to eliminate all these 
abundant proteins before peptides profiling. Weak cation 
exchange magnetic beads (MB-WCX) method is one of the 
established fractionation methods that have high capturing 
ability of low abundance proteins or peptides in serum 
samples [31]. Proteomic/peptidomic studies necessitate a 
sensitive and high-throughput technique. Both matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) have been applied widely 
to the analysis of serum/plasma, saliva and urine samples to 
diagnose human diseases as well as for the identification of 
potential biomarkers of health status [32, 33].
This study aimed to determine serum peptides 
biomarkers for CRC by MALDI-TOF MS combined 
with MB-WCX. A peptide diagnostic panel based on a 
set of potential peptide biomarkers was generated from 
a discovery cohort, and then further tested in another 
independent validation cohort. The identification of these 
peptides was performed using LC-MS/MS.
RESULTS
Characteristics of participants
The demographic and clinical characteristics 
of the participants in the two independent cohorts are 
summarized in Table 1. No significant differences were 
found in the distributions of age and gender between the 
CRC patients and controls (all P > 0.05). In the discovery 
cohort, 15.0% of the patients had early stage cancers 
(tumor-node-metastasis (TNM) stage I or II), where the 
remaining 85.0% had advanced stage cancers (TNM 
stage III or IV). In the validation cohort, 15.4% of the 
patients had early stage cancers (TNM stage I or II) and 
the remaining 84.6% had advanced stage cancers (TNM 
stage III or IV).
Selection of candidate peptides
The discovery cohort was used to select candidate 
peptides. The mass spectra of the serum samples from 
100 CRC patients and 100 controls were obtained using 
MALDI-TOF MS (Figure 1). Among the 224 peptide peaks 
detected in the m/z range from 1,000 to 10,000, 22 peaks 
were detected in at least 50% of the serum samples. Out 
of these 22 peptide peaks, 10 peaks (m/z 1895.3, 1944.0, 
2020.9, 2080.7, 2104.5, 2656.8, 3154.9, 3238.5, 3875.9 
and 4042.8) in the patients were significantly different 
from those in the controls and were selected as candidate 
peptides for further analysis (P < 0.05). Among these 10 
candidate peptides, 3 peptides (peaks at m/z 1895.3, 2020.9 
and 3238.5) were at significantly higher levels, whereas the 
remaining 7 peptides (peaks at m/z 1944.0, 2080.7, 2104.5, 
2656.8, 3154.9, 3875.9 and 4042.8) were at significantly 
lower levels in CRC patients compared with those of the 
controls (Figure 2). The area under the curve (AUC) was 
calculated to show the discriminatory power of these 10 
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candidate peptides, resulting a range from 0.623 to 0.980 of 
AUC in the discovery cohort (Table 2).
Establishment of the peptide diagnostic panel
To improve diagnostic accuracy for CRC, a 
multivariate binary logistic regression analysis was 
performed to establish a diagnostic panel with these 10 
candidate peptides. The stepwise method (entry criteria: 
P < 0.05 and exclusion criteria: P > 0.10) was used to 
select the best panel of peptides. Consequently, 5 peptides 
(peaks at m/z 1895.3, 2020.9, 2080.7, 2656.8, and 3238.5) 
were selected in the diagnostic panel (Table 3). Receiver 
operating characteristic (ROC) curve and the AUC were 
used to assess the diagnostic performance of the panel. 
The panel yielded an accuracy of 95.5%, sensitivity of 
96.0%, specificity of 95.0%, and AUC of 0.982, indicating 
a high discriminatory power (Figure 3 and Table 4).
Table 1: Demographic and clinical characteristics of the participants
Characteristics Discovery cohort Validation cohort
CRC patients Controls P-value CRC patients Controls P-value
Participants numbers 100 100 - 91 91 -
Age (years) 63.65±11.61 61.36±8.30 0.110 63.03±12.72 62.35±12.03 0.771
Gender (male/female) 57/43 57/43 1.000 50/41 50/41 1.000
TNM stage
 I (%) 3 (3.0%) - - 5 (5.5%) - -
 II (%) 12 (12.0%) - - 9 (9.9%) - -
 III (%) 58 (58.0%) - - 29 (31.9%) - -
 IV (%) 27(27.0%) - - 48 (52.7%) - -
Student t test for age and chi-square test for gender. P-value lower than 0.05 was considered statistically significant.
Figure 1: The MALDI-TOF spectra of the serum samples from a CRC patient and a healthy control. The green line 
indicated the mass spectra of a CRC patient and the red line indicated the mass spectra of a healthy individual. X-axis, mass-to-charge ratio 
(m/z); Y-axis, relative intensity.
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External validation of the peptide diagnostic 
panel
The same parameters generated from the discovery 
cohort were then used in the validation cohort to validate 
the diagnostic performance of the peptide diagnostic 
panel. The diagnostic panel yielded an accuracy of 91.8%, 
sensitivity of 95.6%, specificity of 87.9%, and AUC of 
0.932 in the validation cohort, with similar results found 
in the discovery cohort (Figure 3 and Table 4).
Peptide identification
By LC-MS/MS detection, the amino acid sequences 
of 3 peptides (peaks at m/z 1895.3, 2020.9, 3238.5) 
were identified as the partial sequences of complement 
component 4 (C4), complement component 3 (C3) and 
fibrinogen α chain (FGA), respectively (Table 5). However, 
we failed to identify the amino acid sequences of peptide 
peaks at m/z 2080.7 and 2656.8. The unknown modification 
on peptides may contribute to this phenomenon [34].
DISCUSSION
Various studies have suggested that serum peptidome 
is a promising tool for the effective identification of CRC 
patients [20–30]. Although the discriminatory peptides 
were not consistent among those studies because of the 
diverse methodology of sample preparation, measurement 
Figure 2: Box plots of peaks intensity in discovery cohort. Results are presented as box and whisker plots: median, middle lines; 
25-75th percentiles, rectangles; range, lines; outliers, markers.
Table 2: Characteristics of candidate biomarkers in both discovery and validation cohorts
m/z Tendency1 Discovery cohort Validation cohort
Ave (C)2 Ave (N)3 P-value4 AUC5 95% CI6 Ave(C)2 Ave (N)3 P-value4 AUC5 95% CI6
1895.3 ↑ 2664.8 374.7 <0.001 0.838 (0.780-0.895) 2949.0 499.7 <0.001 0.845 (0.783-0.906)
1944.0 ↓ 858.5 3103.8 <0.001 0.906 (0.863-0.949) 918.3 2741.0 <0.001 0.841 (0.782-0.901)
2020.9 ↑ 3328.8 320.5 <0.001 0.746 (0.671-0.822) 4562.3 911.0 <0.001 0.823 (0.754-0.892)
2080.7 ↓ 295.8 1187.9 <0.001 0.896 (0.849-0.942) 221.2 1016.4 <0.001 0.893 (0.844-0.943)
2104.5 ↓ 132.8 544.7 <0.001 0.906 (0.864-0.948) 90.0 511.1 <0.001 0.934 (0.896-0.971)
2656.8 ↓ 565.6 704.3 <0.001 0.673 (0.597-0.750) 471.7 696.4 <0.001 0.699 (0.621-0.777)
3154.9 ↓ 145.8 1566.3 <0.001 0.980 (0.963-0.996) 132.6 1330.0 <0.001 0.918 (0.872-0.963)
3238.5 ↑ 1015.9 451.2 <0.001 0.623 (0.545-0.701) 680.4 456.9 0.456 0.535 (0.450-0.619)
3875.9 ↓ 349.7 557.3 <0.001 0.733 (0.660-0.806) 248.3 509.1 <0.001 0.759 (0.685-0.834)
4042.8 ↓ 271.5 940.5 <0.001 0.859 (0.802-0.916) 112.1 824.1 <0.001 0.897 (0.849-0.945)
1 Tendency↑represent the peaks intensity of CRC patients was higher than the controls,↓represent the peaks intensity of the 
CRC patients was lower than the controls; 2 Average intensity of peaks for the CRC patients; 3 Average intensity of peaks 
for the controls; 4 P-value calculated with the Wilcoxon test; 5 Area under ROC  curve; 6 95% confidence intervals; P-value 
lower than 0.05 was considered statistically significant.
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and/or data processing, there were some common features 
of those studies [35]. For example, all the diagnostic 
models yielded high accuracies. Moreover, fragment of 
C3 was reported as a candidate biomarker in three reports 
[25, 27, 30]. In our study, we utilized MB-WCX coupled 
with MALDI-TOF MS to analyse 382 serum samples. 
We established a promising diagnostic panel to diagnose 
CRC with 5 serum peptides (peaks at m/z 1895.3, 2020.9, 
2080.7, 2656.8 and 3238.5). The diagnostic panel was 
able to discriminate CRC patients from healthy controls 
with high accuracy (discovery cohort: accuracy 95.5%, 
sensitivity 96.0%, specificity 95.0% and AUC 0.982; 
independent validation cohort: accuracy 91.8%, sensitivity 
95.6%, specificity 87.9% and AUC 0.932). In addition, 
three diagnostic peptides were identified as fragments 
of C4, C3 and FGA, respectively. The identification and 
functional analysis of the discriminating peptides might 
provide new insights into cancer behaviours.
External validation is a critical step in introducing 
a new diagnostic model, as it evaluates the performance 
and transportability of a model using data that were not 
included in the model construction. Most of diagnostic 
models of CRC either had no validations [26], or had 
only internal validations, while only three studies were 
externally validated [23, 24, 30] (Table 6). In this study, 
we developed and validated the diagnostic panel with high 
sensitivity and specificity in both discovery and validation 
cohorts with relative large samples, suggesting that the 
established diagnostic panel may have a potential of high 
performance in generalization.
Several potential peptide biomarkers, arising from 
apolipoprotein A-1, apolipoprotein C-1, C3, C4 and 
serine/threonine kinase 4 (STK4) have been identified by 
previous studies [23, 25–27]. Consistent with the reports of 
Pietrowska et al (2011) [25] and Ward et al (2006) [27], we 
also identified C3 peptides and C4 peptides as candidate 
biomarkers for CRC. C3 and C4 play critical roles in the 
activation of the complement system [36]. The excessive 
complement activation and complement deficiencies may 
contribute to several diseases and pathological conditions 
[37]. Increased complement activity was observed in 
cancer [38], while decreased complement activity has 
Figure 3: ROC curves of peptide diagnostic panel in the discovery and validation cohorts. ROC curves illustrating the 
performance of peptide diagnostic panel in discriminating CRC patients from healthy controls.
Table 3: Diagnostic panel in the discovery cohort
m/z β OR 95% CI P-value
1895.3 0.104 1.110 (1.007-1.223) 0.036
2020.9 0.180 1.197 (1.045-1.371) 0.010
2080.7 -0.118 0.888 (0.797-0.990) 0.032
2656.8 -0.525 0.592 (0.467-0.750) <0.001
3238.5 0.481 1.617 (1.330-1.966) <0.001
Constant -1.237 0.290 0.088
P-value lower than 0.05 was considered statistically significant. β, regression coefficient; OR, odds ratio; CI, confidence 
interval.
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been observed in bacterial infections [39, 40]. Patients 
with active lupus erythematosus may have lower levels 
of C3 and C4 than healthy controls [41]. The complement 
system is a central part of immune system regarded as the 
first defence against “non-self” cells [42]. It contributes to 
immune cell activation, pathogen elimination and immune 
surveillance against cancer [43]. Neoplastic transformation 
of tumour cells can generate tumour-associated antigens 
that distinguish malignant cells form normal ones. The 
components of the complement play a role in anti-tumour 
immune response through complement-dependent cellular 
cytotoxicity (CDCC) [44]. Various studies demonstrated 
that certain tumour cells activate complements. Elevated 
levels of C3 are present in patients with ovarian cancer 
[45]. The lectin pathway of complement activation has 
been found to be significantly increased in patients with 
CRC [46]. High expression of complement regulatory 
proteins were associated with poor prognosis of CRC [47]. 
Our results indicated the possibility of use of complement-
related proteins/peptides as new cancer biomarkers. A 
more systematic analysis of abnormalities in the levels of 
complement-related proteins/peptides occurring in serum 
of cancer patients is needed, which can also contribute to 
better understanding of the dynamic interplay between 
CRC and complements.
The peak at m/z 3238.5 identified as a fragment 
of FGA, showed a higher intensity in the CRC patients 
compared to the healthy controls. This peptide may 
reflect the status of high fibrinogen level in CRC patients. 
Fibrinogen is a serum protein secreted by hepatocytes and 
plays a central role in coagulation [48]. Elevated fibrinogen 
level is associated with malignant growth and hematogenous 
metastasis [49, 50]. The fibrinogen receptors of malignant 
cells can bind the fibrinogen. The excessive fibrinogen may 
act as a physical barrier that can protect the malignant cells 
from the NK-mediated killing. Thus, high fibrinogen level 
enhances the early survival of tumour cells by protecting 
malignant cells from eliminating by the innate immune 
system [51]. Several studies have reported that increase of 
plasma fibrinogen level in patients with various types of 
malignancy, including colorectal cancer [52–54], lung cancer 
[55], pancreas cancer [56], ovarian cancer [57] and gastric 
cancer [58].
It is suggested that higher or lower intensities of 
various peptides in cancer serum can be originated not only 
from up- or down-regulation of the parent proteins, but from 
cancer-specific exoprotease activities as well. It has been 
proved that profiling of exoproteases is altered in several 
cancers, e.g., ectopeptidasea CD10, CD13, CD26 and CD143 
are up-regulated in gastric cancer [59] and methionine 
aminopeptidase 2 are up-regulated in colorectal cancer [60]. 
Our work was based on the hypothesis that the different 
peptide patterns observed in controls and cancer patients 
were caused by the cancer-specific exoprotease activities. 
Table 5: Identified candidate peptide biomarkers for CRC
m/z Sequence Protein name
1895.3 R.NGFKSHALQLNNRQIR.G Complement component 4 (C4)
2020.9 R.SSKITHRIHWESASLLR.S Complement component 3 (C3)
2080.7 N/A N/A
2656.8 N/A N/A
3238.5 K.SYKMADEAGSEADHEGTHSTKRGHAKSRPV.R Fibrinogen α chain (FGA)
Table 4: Diagnostic performance of the diagnostic panel in the discovery and validation cohorts
Diagnostic 
group
Real group Accuracy 
rate
Sensitivity
(95% CI)
Specificity
(95% CI)
AUC  
(95% CI)
P-value
CRC 
patients
Controls
Discovery 
cohort
CRC 
patients 96 5 95.5% 96.0% 95.0% 0.982 <0.001
(n=200) Controls 4 95 (92.2%-99.8%) (90.7%-99.3%) (0.965-0.998)
Validation 
cohort
CRC 
patients 87 11 91.8% 95.6% 87.9% 0.932 <0.001
(n=182) Controls 4 80 (91.6%-99.6%) (81.5%-94.3%) (0.892-0.973)
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Although C3, C4 and FGA are not CRC-specific biomarkers, 
the profiling of CRC-specific peptide pattern and/or CRC-
specific peptide sequence has potential value in diagnosis 
of CRC. Additionally, biomarker discovery at OMICs 
level is moving away from the idealized single cancer-
specific biomarker. Seldom there is a single biomarker 
with both high levels of specificity and sensitivity that can 
meet the requirement for routine clinical practices, due to 
the molecular heterogeneity of tumours [19]. Although an 
individual biomarker maybe specific and sensitive only for a 
certain molecular aetiology, combinations of many markers 
can transcend the heterogeneity to reach higher specificity 
and sensitivity. Thus, the cancer-specific peptide panel may 
play a crucial role in the diagnosis of cancers.
There were several limitations of this study must be 
demonstrated. Due to the small sample size of the early-
stage patients in the cohorts, we were unable to compare 
the differences in peptides between the early-stage patients 
and the healthy controls. This weakness may restrict the 
clinical value of the panel in early detection of CRC. Further 
case-control study including more early-stage patients or 
a prospective cohort study in design should be performed 
to determine the diagnostic value of the peptide panel. In 
addition, the peptides are fragments of proteins involved in 
acute phase and inflammatory response. Thus, the specificity 
of proposed biomarkers may be doubted. Further studies 
including functional analysis are essential to answer this 
question. Finally, because of the identification of proteases 
was not our primary goal of the study, we did not research 
the cancer-specific proteases activities. Studies that focus on 
cancer-specific proteases activities may shed light on CRC 
pathophysiology and find possible targets for CRC therapy.
In conclusion, using MALDI-TOF MS and LC-
MS/MS, we have characterized 5 peptides (peaks at 
m/z 1895.3, 2020.9, 2080.7, 2656.8 and 3238.5) to be 
novel candidate biomarkers for CRC diagnosis. We 
have constructed a peptide diagnostic panel that could 
diagnose CRC with an accuracy of 91.8%, sensitivity of 
Table 6: The comparison of the present study with similar studies
Studies MS 
methods
Population Discovery 
cohort 
(CRC/
control)
Validation 
cohort 
(CRC/
control)
Validation 
methods
Sensitivity Specificity Identification
The present 
study
MALDI-
TOF Asians 100/100 91/91
External 
validation 95.6% 87.9% C4, C3, FGA
Fan et al 2012 
[20]
MALDI-
TOF Asians 38/32 34/33
Split 
samples 94.1% 100% ----
Deng et al 
2014 [21]
MALDI-
TOF Asians 33/32 34/33
Split 
samples 100% 100% ----
De Noo et al 
2006[22]
MALDI-
TOF Caucasians 66/50 ----
Cross-
validation 95.2% 90.0% ----
Engwegen 
 et al 2006 [23]
SELDI-
TOF Caucasians 40/49 37/31
External 
validation 89.5% 88.9% Apolipoprotein C1, A1
Liu et al 2009 
[24]
SELDI-
TOF Asians 74/48 60/39
External 
validation 95.0% 94.78% ----
Pietrowska  
et al 2011[25]
MALDI-
TOF Caucasians 35/45 ----
Cross-
validation 68.6% 81.9% C4A, C3
Zhai et al 2012 
[26]
SELDI-
TOF Asians 73/26 ----
No 
validation ---- ---- STK4
Ward et al 
2006 [27]
SELDI-
TOF Caucasians 62/31 ----
Cross-
validation 94.0% 96.0%
C3a, Apolipoprotein 
C1
Yu et al 
2004[28]
SELDI-
TOF Asians 55/92 ----
Cross-
validation 89.0% 92.0% ----
Chen et al 
2004 [29]
SELDI-
TOF Asians 55/92 ----
Cross-
validation 91.0% 93.0% ----
Habermann  
et al 2006 [30]
SELDI-
TOF Caucasians 58/32 38/21
External 
validation 96.8% 96.2% C3a
SLEDI-TOF MS, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry; MALDI-TOF MS, matrix-
assisted laser desorption/ionization time-of flight mass spectrometry; STK4, serine/threonine kinase 4; C3, complement 
component 3; C4, complement component 4; FGA, Fibrinogen α chain.
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95.6%, specificity of 87.9% and AUC value of 0.932. As 
a diagnostic panel, there is potential for this method to 
provide an in vitro diagnosis tool for CRC. We have also 
identified the amino acid sequences of peptides fragments 
(peaks at m/z 1895.3, 2020.9 and 3238.5) from C3, C4 and 
FGA, suggesting that increased levels of C3, C4 and FGA 
might associate with the pathogenesis of CRC.
MATERIALS AND METHODS
Participants
The discovery cohort containing 100 patients with 
CRC and 100 healthy individuals recruited from Beijing 
Shijitan Hospital between January 2013 and December 
2014. The independent validation cohort consisted of 91 
patients with CRC and 91 healthy participants recruited 
from another hospital, Beijing Friendship Hospital, between 
March 2011 and December 2012. Each CRC patient 
underwent a colonoscopic biopsy and was diagnosed by two 
senior pathologists according to World Health Organization 
(WHO) diagnostic criteria [61]. Pathological samples were 
classified according to the TNM stage classification system 
[61]. All healthy controls and CRC patients were gender- 
and age- matched.
Controls should meet the following inclusion 
criteria: (1) older than 18 years old, (2) capable of giving 
informed consent, and (3) confirmed to be healthy without 
any diseases detected during physical examination. 
Controls were excluded if they met any of the following 
criteria: (1) had previous history of cancer, (2) had used 
any drugs, and (3) were pregnant or breastfeeding.
The patients with CRC met the following inclusion 
criteria: (1) older than 18 years, (2) capable of giving 
informed consent, and (3) had colorectal cancer. Patients 
were excluded if they had any of the following: (1) other 
cancers; (2) a history of other cancers; (3) a history of 
radiotherapy or chemotherapy; (4) any severe diseases 
concerning the cardiovascular system, respiratory system, 
genitourinary system, digestive system or circulatory 
system; or (5) a systemic infection. The study was 
approved by the ethical committee of Capital Medical 
University, Beijing.
Collection of serum samples
Fasting blood samples from the participants were 
collected in the morning and allowed to clot at 37°C for 
30 mins. All blood samples from the CRC patients were 
obtained before the colorectal surgery. Serum was then 
separated by centrifugation at 3000 rpm for 15 mins and 
then stored at -80°C until further analysis.
Peptides fractionation
All serum samples were fractionated using MB-
WCX kit, according to the instructions provided by the 
supplier (ClinProtTM, Bruker Daltonics, Billerica, MA, 
USA) [62]. The samples were purified and isolated in 
three steps: binding, washing, and elution. Firstly, 10 μl 
beads, 10 μl MB-WCX binding solution and 5 μl serum 
were added in a 0.2 ml polypropylene tube, mixed by 
pipetting up and down several times, and then incubated 
for 5 min. Secondly, the tubes were placed on a magnetic 
bead separator for 1 min and the beads were grasped on 
the tube wall. The supernatant was removed and 100 μl 
of magnetic bead washing solution was added, and mixed 
thoroughly. After three times washing, the bound peptides 
were eluted from the magnetic beads by 5 μl of eluting 
solution.
Peptides profiling by MALDI-TOF MS and 
processing of spectral data
A portion of the eluted sample was diluted (1:10) in 
α-cyano-4-hydroxycinnamic acid (CHCA) matrix solution 
(0.5 g/L CHCA in acetonitrile/water 1:1 v/v containing 
0.1% trifluoroacetic acid) (Sigma-Aldrich, St, Louis, 
MO, USA). Then 1 μl of the mixture was spotted onto a 
MALDI-TOF MS target (Bioyong Tech, Beijing, China) 
and dried at room temperature before analysis. Spectral 
profiles were acquired using a MALDI-TOF MS (Clin-
TOFTM, Bioyong Tech, Beijing, China). The instrument 
was calibrated using a mix of commercial peptide and 
protein calibration standards (Sigma-Aldrich, St, Louis, 
MO, USA) prepared in the same matrix solution as above. 
Spectra were acquired automatically in a 1,000-10,000 
mass-to-change ratio (m/z) range in linear mode. Each 
spectrum was the sum of 1,000 laser shots per spotted 
sample, delivered to different locations on the spot in 10 
sets of 100 shots (at a laser frequency of 10 Hz).
All spectra obtained from the MALDI-TOF MS 
were pre-processed using BioExplorerTM 2.0 (Bioyong 
Tech, Beijing, China) [63]. In brief, the background was 
estimated and then subtracted from each spectrum based 
on local noise estimators. Peaks were detected using 
a signal-to-noise ratio (S/N) cut-off of 5.0, which was 
found to be a good compromise between overdetection 
and sensitivity. To align the spectra, a mass shift of no 
more than 0.1% was determined. Smoothing was applied 
by averaging the intensities within a 5-point width 
moving window followed by baseline subtraction using 
an algorithm based on finding the lowest points between 
dominant local intensity maxima within a particular mass 
window. Normalization was performed by dividing the 
intensity of each data point in a spectrum by the sum of all 
intensities in that spectrum.
Peptide identification by LC-MS/MS
The amino acid sequences of the candidate peptides 
were identified using a nano-liquid chromatography-
electrospray ionization-tandem mass spectrometry (nano-
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LC/ESI-MS/MS) consisting of an AquityTM UPLC system 
(Waters, Milford, MA, USA) and a LTQ Orbitrap XL 
mass spectrometer (Thermo Fisher Scientific, Pittsburgh, 
PA, USA) equipped with a nano-ESI source. A sample 
of 5 μl solution was injected on the column. The mobile 
phase A, mobile phase B, flow rate and gradient elution 
were operated according to the published methods [16]. 
The obtained samples were further analysed using the 
MS/MS instrument. The Mascot 2.4.1 (Matrix Science, 
London, UK) was used to search the database. The results 
were restricted to “Homo sapiens” with the peptide mass 
tolerance set to ±20 ppm and the fragment mass tolerance 
set to ± 0.2 Da.
Statistical analysis
Statistical analyses and displays were performed 
using SPSS 19.0 (IBM Corporation, New York, USA) 
and GraphPad Prism 5.0 (GraphPad, San Diego, USA). 
Normality of variables was tested by Shapiro-Wilk test. 
Student’s t test was used to compare normally distributed 
continuous data, and the Mann-Whitney U-test was used for 
non-normally distributed continuous data. The chi-square 
test was used for the analysis of categorical data. Differential 
peptide peaks were used to establish a diagnostic panel by 
multivariate binary logistic regression. Receiver operating 
characteristic (ROC) curves and the area under the curve 
(AUC) were used to assess the diagnostic performance of 
the model. P < 0.05 was considered statistically significant 
(two-tailed).
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